239 related articles for article (PubMed ID: 37787146)
1. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.
De Meyer S; Blujdea ER; Schaeverbeke J; Reinartz M; Luckett ES; Adamczuk K; Van Laere K; Dupont P; Teunissen CE; Vandenberghe R; Poesen K
Brain; 2024 Mar; 147(3):936-948. PubMed ID: 37787146
[TBL] [Abstract][Full Text] [Related]
2. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
3. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
[TBL] [Abstract][Full Text] [Related]
5. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.
McGrath ER; Beiser AS; O'Donnell A; Yang Q; Ghosh S; Gonzales MM; Himali JJ; Satizabal CL; Johnson KA; Tracy RP; Seshadri S
J Alzheimers Dis; 2022; 87(4):1517-1526. PubMed ID: 35491781
[TBL] [Abstract][Full Text] [Related]
6. Combination of plasma amyloid beta
Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE
Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409
[TBL] [Abstract][Full Text] [Related]
7. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease.
Yakoub Y; Ashton NJ; Strikwerda-Brown C; Montoliu-Gaya L; Karikari TK; Kac PR; Gonzalez-Ortiz F; Gallego-Rudolf J; Meyer PF; St-Onge F; Schöll M; Soucy JP; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
Alzheimers Dement; 2023 Dec; 19(12):5620-5631. PubMed ID: 37294682
[TBL] [Abstract][Full Text] [Related]
9. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.
Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA
Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682
[TBL] [Abstract][Full Text] [Related]
10. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.
Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Zetterberg H; Abramowicz M; Scheffler M; Assal F; Garibotto V; Blennow K; Frisoni GB
Alzheimers Res Ther; 2024 May; 16(1):110. PubMed ID: 38755703
[TBL] [Abstract][Full Text] [Related]
11. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease.
Yang Z; Sreenivasan K; Toledano Strom EN; Osse AML; Pasia LG; Cosme CG; Mugosa MRN; Chevalier EL; Ritter A; Miller JB; Cordes D; Cummings JL; Kinney JW
Alzheimers Res Ther; 2023 Nov; 15(1):190. PubMed ID: 37924152
[TBL] [Abstract][Full Text] [Related]
13. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
[TBL] [Abstract][Full Text] [Related]
14. A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer's Disease Continuum.
Coomans EM; Verberk IMW; Ossenkoppele R; Verfaillie SCJ; Visser D; Gouda M; Tuncel H; Wolters EE; Timmers T; Windhorst AD; Golla SSV; Scheltens P; van WM; Flier D; van Berckel BNM; Teunissen CE
J Nucl Med; 2023 Mar; 64(3):437-443. PubMed ID: 36229187
[TBL] [Abstract][Full Text] [Related]
15. Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease.
Spotorno N; Strandberg O; Vis G; Stomrud E; Nilsson M; Hansson O
Brain; 2023 Apr; 146(4):1602-1614. PubMed ID: 36130332
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
Chatterjee P; Pedrini S; Ashton NJ; Tegg M; Goozee K; Singh AK; Karikari TK; Simrén J; Vanmechelen E; Armstrong NJ; Hone E; Asih PR; Taddei K; Doré V; Villemagne VL; Sohrabi HR; Zetterberg H; Masters CL; Blennow K; Martins RN
Alzheimers Dement; 2022 Jun; 18(6):1141-1154. PubMed ID: 34494715
[TBL] [Abstract][Full Text] [Related]
18. Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults.
Saloner R; VandeVrede L; Asken BM; Paolillo EW; Gontrum EQ; Wolf A; Lario-Lago A; Milà-Alomà M; Triana-Baltzer G; Kolb HC; Dubal DB; Rabinovici GD; Miller BL; Boxer AL; Casaletto KB; Kramer JH
Alzheimers Dement; 2024 Jan; 20(1):376-387. PubMed ID: 37639492
[TBL] [Abstract][Full Text] [Related]
19. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
Ebenau JL; Pelkmans W; Verberk IMW; Verfaillie SCJ; van den Bosch KA; van Leeuwenstijn M; Collij LE; Scheltens P; Prins ND; Barkhof F; van Berckel BNM; Teunissen CE; van der Flier WM
Neurology; 2022 Mar; 98(13):e1315-e1326. PubMed ID: 35110378
[TBL] [Abstract][Full Text] [Related]
20. Tau-related grey matter network breakdown across the Alzheimer's disease continuum.
Pelkmans W; Ossenkoppele R; Dicks E; Strandberg O; Barkhof F; Tijms BM; Pereira JB; Hansson O
Alzheimers Res Ther; 2021 Aug; 13(1):138. PubMed ID: 34389066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]